Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 2
1983 1
1985 2
1986 1
1987 1
1988 2
1989 2
1990 2
1991 5
1992 2
1994 2
1995 1
1996 2
1997 7
1998 1
1999 1
2000 4
2001 5
2002 2
2003 2
2004 3
2005 6
2006 4
2008 4
2009 4
2010 1
2011 6
2012 6
2013 3
2014 3
2015 1
2016 4
2017 5
2018 2
2019 2
2020 4
2021 2
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

98 results

Results by year

Filters applied: . Clear all
Page 1
Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial.
Bourhis J, Sire C, Graff P, Grégoire V, Maingon P, Calais G, Gery B, Martin L, Alfonsi M, Desprez P, Pignon T, Bardet E, Rives M, Geoffrois L, Daly-Schveitzer N, Sen S, Tuchais C, Dupuis O, Guerif S, Lapeyre M, Favrel V, Hamoir M, Lusinchi A, Temam S, Pinna A, Tao YG, Blanchard P, Aupérin A. Bourhis J, et al. Lancet Oncol. 2012 Feb;13(2):145-53. doi: 10.1016/S1470-2045(11)70346-1. Epub 2012 Jan 18. Lancet Oncol. 2012. PMID: 22261362 Clinical Trial.
We aimed to assess the efficacy and safety of a combination of these approaches. METHODS: In our open-label phase 3 randomised trial, we enrolled patients with locally advanced, stage III and IV (non-metastatic) HNSCC and an Eastern Cooperative Oncology Group perfor …
We aimed to assess the efficacy and safety of a combination of these approaches. METHODS: In our open-label phase 3 randomised tri …
Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients.
Le Louedec F, Alix-Panabières C, Lafont T, Allal BC, Garrel R, Digue L, Guigay J, Cupissol D, Delord JP, Lallemant B, Alfonsi M, Aubry K, Mazel M, Becher F, Perriard F, Chatelut E, Thomas F. Le Louedec F, et al. Br J Clin Pharmacol. 2019 Jun;85(6):1357-1366. doi: 10.1111/bcp.13907. Epub 2019 Apr 13. Br J Clin Pharmacol. 2019. PMID: 30811063 Free PMC article. Clinical Trial.
Long-Term Update of NRG/RTOG 0522: A Randomized Phase 3 Trial of Concurrent Radiation and Cisplatin With or Without Cetuximab in Locoregionally Advanced Head and Neck Cancer.
Caudell JJ, Torres-Saavedra PA, Rosenthal DI, Axelrod RS, Nguyen-Tan PF, Sherman EJ, Weber RS, Galvin JM, El-Naggar AK, Konski AA, Echevarria MI, Dunlap NE, Shenouda G, Singh AK, Beitler JJ, Garsa A, Bonner JA, Garden AS, Algan O, Harris J, Le QT. Caudell JJ, et al. Int J Radiat Oncol Biol Phys. 2023 Jul 1;116(3):533-543. doi: 10.1016/j.ijrobp.2022.12.015. Epub 2022 Dec 19. Int J Radiat Oncol Biol Phys. 2023. PMID: 36549347 Free PMC article. Clinical Trial.
PURPOSE: The combination of cisplatin and radiation or cetuximab and radiation improves overall survival of patients with locoregionally advanced head and neck carcinoma. NRG Oncology conducted a phase 3 trial to test the hypothesis that …
PURPOSE: The combination of cisplatin and radiation or cetuximab and radiation improves overall survival of patients with locoregionally …
Pretreatment probability model for predicting outcome after intraarterial chemoradiation for advanced head and neck carcinoma.
van den Broek GB, Rasch CR, Pameijer FA, Peter E, van den Brekel MW, Tan IB, Schornagel JH, de Bois JA, Zijp LJ, Balm AJ. van den Broek GB, et al. Cancer. 2004 Oct 15;101(8):1809-17. doi: 10.1002/cncr.20556. Cancer. 2004. PMID: 15386309 Free article. Review.
BACKGROUND: Concurrent chemoradiation is being used increasingly to treat patients with advanced-stage head and neck carcinoma. In the current study, a clinical nomogram was developed to predict local control and overall survival rates for individual patients who will unde …
BACKGROUND: Concurrent chemoradiation is being used increasingly to treat patients with advanced-stage head and neck carcinoma. In the curre …
Gemcitabine concurrent with radiation therapy for locally advanced head and neck carcinomas.
Chauhan A, Singh H, Sharma T, Manocha KK. Chauhan A, et al. Afr Health Sci. 2008 Sep;8(3):149-55. Afr Health Sci. 2008. PMID: 19357741 Free PMC article. Clinical Trial.
BACKGROUND: Management of advanced head and neck carcinoma is a challenging proposition. Presently concomitant chemo-irradiation has become the standard of care in such patients. ...PATIENTS AND METHODS: From November 2000 to March 2003, eighty …
BACKGROUND: Management of advanced head and neck carcinoma is a challenging proposition. Presently concom …
Randomized trial on acute toxicities of weekly vs three-weekly cisplatin-based chemoradiation in head and neck cancer.
Ameri A, Norouzi S, Sourati A, Azghandi S, Novin K, Taghizadeh-Hesary F. Ameri A, et al. Cancer Rep (Hoboken). 2022 Jan;5(1):e1425. doi: 10.1002/cnr2.1425. Epub 2021 Jun 7. Cancer Rep (Hoboken). 2022. PMID: 34101389 Free PMC article. Clinical Trial.
BACKGROUND: The current first-line treatment of locally advanced head and neck carcinoma (LAHNC) is concurrent chemoradiation with three-weekly cisplatin 100 mg/m(2) . ...AIM: To compare the acute hematologic and renal toxicities of these two re …
BACKGROUND: The current first-line treatment of locally advanced head and neck carcinoma (LAHNC) is concu …
Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522.
Truong MT, Zhang Q, Rosenthal DI, List M, Axelrod R, Sherman E, Weber R, Nguyen-Tân PF, El-Naggar A, Konski A, Galvin J, Schwartz D, Trotti A, Silverman C, Singh A, Godette K, Bonner JA, Jones CU, Garden AS, Shenouda G, Matthiesen C, Le QT, Bruner D. Truong MT, et al. Int J Radiat Oncol Biol Phys. 2017 Mar 15;97(4):687-699. doi: 10.1016/j.ijrobp.2016.08.003. Epub 2016 Aug 12. Int J Radiat Oncol Biol Phys. 2017. PMID: 27727066 Free PMC article. Clinical Trial.
PURPOSE: To analyze the quality of life (QOL) and performance status (PS) (secondary outcome) in patients with stage III to IV head and neck cancer (HNC) enrolled on a prospective randomized phase 3 trial comparing radiation-cisplatin without cetuximab (CIS) or with …
PURPOSE: To analyze the quality of life (QOL) and performance status (PS) (secondary outcome) in patients with stage III to IV head and neck …
Feasibility of concomitant cisplatin with hypofractionated radiotherapy for locally advanced head and neck squamous cell carcinoma.
Jacinto AA, Batalha Filho ES, Viana LS, De Marchi P, Capuzzo RC, Gama RR, Boldrini Junior D, Santos CR, Pinto GDJ, Dias JM, Canton HP, Carvalho R, Radicchi LA, Bentzen S, Zubizarreta E, Carvalho AL. Jacinto AA, et al. BMC Cancer. 2018 Oct 23;18(1):1026. doi: 10.1186/s12885-018-4893-5. BMC Cancer. 2018. PMID: 30352576 Free PMC article. Clinical Trial.
METHODS: This single-arm trial was designed to evaluate the safety and feasibility of HYP-RT with concomitant CDDP in LAHNC. ...A feeding tube was necessary for most patients during treatment. Further investigation of this strategy is warranted. TRIAL REGISTRATION: …
METHODS: This single-arm trial was designed to evaluate the safety and feasibility of HYP-RT with concomitant CDDP in LAHNC. ...A fee …
Evaluation of dosimetric and volumetric changes in target volumes and organs at risk during adaptive radiotherapy in head and neck cancer: A prospective study.
Chophy A, Gupta S, Singh P, Sharma N, Krishnan AS, Namitha RS, Roushan R, Rastogi A, Nair S, Diundi A, Raju MC, Joseph D, Gupta M. Chophy A, et al. J Med Imaging Radiat Sci. 2023 Jun;54(2):306-311. doi: 10.1016/j.jmir.2023.02.005. Epub 2023 Mar 1. J Med Imaging Radiat Sci. 2023. PMID: 36868903
In the present study, dosimetric and volumetric changes in target volumes and organs at risk during adaptive radiotherapy in head and neck cancer was evaluated. MATERIAL AND METHODS: Thirty-four locally advanced Head and neck carcinoma patients …
In the present study, dosimetric and volumetric changes in target volumes and organs at risk during adaptive radiotherapy in head and neck c …
ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy.
Guberina M, Sak A, Pöttgen C, Tinhofer-Keilholz I, Budach V, Balermpas P, Von der Grün J, Rödel CM, Gkika E, Grosu AL, Abdollahi A, Debus J, Belka C, Pigorsch S, Combs SE, Mönnich D, Zips D, De-Colle C, Welz S, Linge A, Lohaus F, Baretton G, Gauler T, Baumann M, Krause M, Schuler M, Bankfalvi A, Höing B, Lang S, Stuschke M. Guberina M, et al. Pharmacogenomics J. 2021 Feb;21(1):37-46. doi: 10.1038/s41397-020-0174-1. Epub 2020 Jun 16. Pharmacogenomics J. 2021. PMID: 32546699 Free PMC article.
Identifying patients with locally advanced head and neck carcinoma on high risk of recurrence after definitive concurrent radiochemotherapy is of key importance for the selection for consolidation therapy and for individualized treatment intensi …
Identifying patients with locally advanced head and neck carcinoma on high risk of recurrence after defin …
98 results